Fractyl Health (NASDAQ:GUTS) Director Buys $19,550.00 in Stock

Fractyl Health, Inc. (NASDAQ:GUTS) Director Ajay Royan bought 23,000 shares of the firm’s stock in a transaction dated Friday, June 12th. The stock was bought at an average cost of $0.85 per share, with a total value of $19,550.00. Following the transaction, the director directly owned 40,901 shares of the company’s stock, valued at approximately $34,765.85. This trade represents a 128.48% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

Fractyl Health Price Performance

Shares of NASDAQ GUTS opened at $0.85 on Thursday. Fractyl Health, Inc. has a 1-year low of $0.38 and a 1-year high of $2.45. The business has a 50-day moving average of $0.72 and a 200-day moving average of $1.06. The company has a debt-to-equity ratio of 1.41, a current ratio of 4.28 and a quick ratio of 4.28. The company has a market capitalization of $134.85 million, a price-to-earnings ratio of -0.66 and a beta of 2.34.

Fractyl Health (NASDAQ:GUTS) last issued its earnings results on Tuesday, May 12th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.23. On average, equities analysts anticipate that Fractyl Health, Inc. will post -0.6 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of GUTS. FNY Investment Advisers LLC purchased a new position in Fractyl Health in the third quarter valued at about $31,000. Jane Street Group LLC purchased a new position in Fractyl Health in the second quarter valued at about $31,000. Accredited Investors Inc. acquired a new stake in Fractyl Health during the first quarter valued at approximately $46,000. Scientech Research LLC acquired a new stake in Fractyl Health during the third quarter valued at approximately $49,000. Finally, Prelude Capital Management LLC acquired a new stake in Fractyl Health during the third quarter valued at approximately $55,000.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on GUTS. HC Wainwright reissued a “buy” rating and issued a $8.00 price target on shares of Fractyl Health in a report on Thursday, June 4th. Canaccord Genuity Group reissued a “buy” rating and issued a $8.00 price target on shares of Fractyl Health in a report on Thursday, March 26th. Weiss Ratings reissued a “sell (e+)” rating on shares of Fractyl Health in a report on Tuesday, May 12th. Finally, Wall Street Zen raised Fractyl Health from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Fractyl Health has an average rating of “Hold” and an average price target of $5.40.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.